e-learning
resources
Breathe
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?
Victor A. Adepoju
Source:
Breathe, 15 (4) 353; 10.1183/20734735.0257-2019
Journal Issue:
December
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Victor A. Adepoju. Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?. Breathe, 15 (4) 353; 10.1183/20734735.0257-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019
Year: 2019
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019
Year: 2019
May the value of FEV1 be helpful in the choice of the antibiotic therapy in acute exacerbation of COPD?
Source: Eur Respir J 2001; 18: Suppl. 33, 189s
Year: 2001
Is antibiotic treatment during asthma exacerbation necessary ?
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?
Source: Eur Respir J, 57 (2) 2002122; 10.1183/13993003.02122-2020
Year: 2021
Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis
Source: Eur Respir Rev 2017; 26: 160073
Year: 2017
Can antibiotics prevent acute COPD exacerbation? A systematic review and meta-analysis
Source: Annual Congress 2013 –COPD: acute exacerbations and others
Year: 2013
What is the role of prophylactic antibiotic therapy in chronic bronchitis or COPD?
Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new?
Year: 2009
Antibiotic effectiveness to prevent new chronic obstructive pulmonary disease (COPD) exacerbations in current medical practice
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009
COPD: antibiotic strategy in infectious exacerbations
Source: Eur Respir J 2001; 18: Suppl. 33, 137s
Year: 2001
Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD
Source: Eur Respir J 2009; 33: 282-288
Year: 2009
Which patients with COPD can potentially benefit from prophylactic use of antibiotics?
Source: Annual Congress 2007 - Different aspects of COPD exacerbations
Year: 2007
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
What is the best biomarker of COPD stability?
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Prudent use of antibiotics: acute exacerbation of COPD as an example
Source: Eur Respir J 2010; 36: 983-985
Year: 2010
Does having previous sputum results improve rationalisation of antimicrobial prescribing during acute exacerbations of COPD?
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept